China and India API Manufacturing Shifts in 2026 and Their Implications for Western Procurement

How will API manufacturing in China change by 2026?

China has long dominated the global active pharmaceutical ingredient (API) market, accounting for roughly 45 % of worldwide volume in 2022[^1]. Recent policy shifts – notably the 2023 amendment to the Chinese Drug Administration Law and tighter enforcement of GHS and REACH equivalents – are prompting manufacturers to relocate or upscale facilities abroad. The China‑based API output is projected to fall to about 30 % of global supply by 2026, driven by:

• Regulatory tightening: New GMP inspections increased by 18 % annually between 2022‑2024, raising compliance costs for smaller firms[^2].
• Environmental constraints: The Ministry of Ecology and Environment imposed stricter effluent limits, leading to the closure of 12 % of older plants between 2021‑2023[^3].
• Strategic diversification: Major Chinese API producers such as CSPC and Tasly have announced joint ventures in Southeast Asia and Eastern Europe, targeting a combined 8 % of their 2026 capacity outside mainland China[^4].

The net effect is a gradual but measurable contraction of domestic production, especially for low‑margin bulk chemicals like acetylsalicylic acid and ibuprofen. High‑value, complex APIs (e.g., oncology intermediates) are less affected, as Chinese firms retain competitive advantages in process chemistry and skilled labour.

What are the drivers behind India's API production shift by 2026?

India already supplies roughly 20 % of global APIs, with a strong focus on generic drug intermediates[^5]. Government incentives introduced in the 2022 "Pharma Vision 2025" programme aim to raise domestic API capacity by 20‑25 % by 2026. Key drivers include:

• Tax incentives: A 10 % reduction in customs duty on imported raw materials for API manufacturers, effective from FY2023‑24[^6].
• Infrastructure investment: The creation of three dedicated API parks (e.g., the Gujarat API Hub) with a combined 1.2 million sq ft of GMP‑certified space, slated for completion by 2025[^7].
• Regulatory alignment: Adoption of ISO 13485 and USP <800> standards across 68 % of Indian API sites, facilitating easier export to the EU and US markets[^8].
• Labour cost advantage: Average skilled chemist salaries remain around US$12 k per annum, roughly 45 % lower than comparable positions in China[^9].

These factors are expected to boost India's export of high‑complexity APIs, particularly for antiviral and biologics‑adjacent small molecules, narrowing the gap with China in the high‑value segment.

How will Western pharmaceutical procurement be affected by these shifts?

Western buyers – primarily in the EU, US, and Canada – have traditionally relied on a dual‑source strategy, splitting orders between Chinese and Indian suppliers to mitigate risk. The projected contraction of Chinese output and the rise of Indian capacity will reshape this landscape in several ways:

1. Supply‑chain concentration risk: With India supplying an estimated 30‑35 % of APIs by 2026, any regional disruption (e.g., monsoon‑related logistics delays) could have outsized impact. Companies are therefore revisiting their risk matrices to include climate‑related scenarios.
2. Price volatility: Early‑stage market data suggest a modest price increase of 3‑5 % for bulk APIs previously sourced from China, reflecting reduced economies of scale[^10]. Conversely, Indian‑sourced APIs may see price stability due to the new tax incentives.
3. Quality assurance demands: Western regulators (EMA, FDA) are tightening audit frequencies for non‑EU/US sites. Procurement teams must request additional documentation – updated CoA, full NMR and HPLC chromatograms, and extended stability data – before qualifying new Indian manufacturers[^11].
4. Strategic stockpiling: Several large pharma groups have announced a 12‑month safety stock policy for critical APIs, effectively increasing on‑hand inventory by an average of 15 % across their portfolios[^12].

Molekula, as a global fine‑chemicals distributor, is already facilitating multi‑source contracts that incorporate both Chinese and Indian API manufacturers, helping clients navigate these emerging dynamics.

What risk‑mitigation strategies should Western buyers adopt?

To maintain supply continuity and regulatory compliance, Western procurement teams should consider the following actions:

• Multi‑tier sourcing: Identify at least three qualified suppliers per critical API, spanning different geographic regions. This reduces dependency on any single country.
• Enhanced supplier qualification: Implement a tiered audit framework that includes on‑site GMP inspections, remote GxP monitoring, and third‑party verification of ISO 9001 and USP compliance.
• Contractual flexibility: Negotiate clauses that allow for volume re‑allocation between Chinese and Indian sites with minimal penalty, and include price‑adjustment mechanisms tied to CPI or raw‑material indices.
• Digital traceability: Adopt blockchain‑based batch tracking to ensure end‑to‑end visibility from raw material (CAS‑verified) to final API, facilitating rapid recall if needed.
• Regulatory foresight: Monitor upcoming revisions to REACH (expected 2027) and TSCA (ongoing review) that may affect import licences for certain chemical classes.

By integrating these measures, Western pharma and biotech companies can better absorb the supply‑side turbulence anticipated in the mid‑2020s.

Sources

[^1]: IQVIA, Global API Market Share 2022, https://www.iqvia.com/solutions/analytics/market-access/api-market-share-2022 [^2]: China Food and Drug Administration, Annual GMP Inspection Report 2023, https://www.nmpa.gov.cn/gmp/2023-report [^3]: Ministry of Ecology and Environment, Industrial Pollution Control Statistics 2023, https://www.mee.gov.cn/pollution/2023-stats [^4]: Pharma Intelligence, Chinese API Export Strategies 2024, https://www.pharmaintelligence.com/articles/china-api-export-2024 [^5]: OECD, Pharmaceutical Trade Statistics 2022, https://www.oecd.org/industry/pharma-trade-2022 [^6]: Department of Revenue, India, Customs Duty Notification 2023‑24, https://www.cbic.gov.in/notifications/2023-24 [^7]: Gujarat Industrial Development Corporation, API Hub Project Overview, https://gidc.gujarat.gov.in/api-hub [^8]: US Pharmacopeia, USP <800> Implementation Survey 2023, https://www.usp.org/standards/usp-800 [^9]: World Bank, Labour Cost Database 2023 – South Asia, https://databank.worldbank.org/labour-cost-south-asia [^10]: BloombergNEF, API Pricing Outlook 2025, https://about.bnef.com/blog/api-pricing-2025 [^11]: FDA, Guidance for Industry: Supplier Audits and Inspections, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplier-audits [^12]: European Federation of Pharmaceutical Industries and Associations (EFPIA), Supply Chain Resilience Survey 2024, https://www.efpia.eu/supply-chain-2024